RAP 0.00% 20.5¢ raptor resources limited

HeraMed's product is nothing revolutionary, doppler based foetal...

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
  1. 1,439 Posts.
    lightbulb Created with Sketch. 860
    HeraMed's product is nothing revolutionary, doppler based foetal monitors already exist and have been approved in the past.

    ResApp's diagnostic product for children is a very different approval process.

    The Global Head of Diagnostics for Roche ($380B Market Cap) Tim Jaeger believes the digital transformation will drive better clinical decisions and diagnosis. They would be all over ResApp.

 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.